

Dehdashti, Seameen (Jean)

From: Dehdashti, Seameen (Jean)
Sent: Monday, November 05, 2018 12:51 PM
To: 'BDV (Barbara Davies)'
Cc: Dehdashti, Seameen (Jean)
Subject: FDA Information Request - Clinical: BLA 125671/0

Importance: High

Dear Barbara,

We are reviewing your BLA submission for Antihemophilic Factor (Recombinant), GlycoPEGylated, turoctocog alfa pegol (STN 125671), and have the following information request (IR), outlined below in **bold text**. Please send us your response by 3:00 PM ET, Friday, November 9, 2018.

FDA Information Request (IR) - Clinical:

- 1. Please provide, in a tabular format, a list of all subjects (with subject IDs) from the main study 3859 who met the prespecified criteria for randomization but who were not randomized. Please list the reason for non-randomization and the regimen that each subject received at the start and at the end of Ext 1. We appreciate if this information could be sent to us in Excel format as well for easier review.**
- 2. In your response to FDA's information request which was provided by email on August 13, 2018, you included an Excel file "Appendix 1 table 2b". Please add the following information to the 9 subjects who switched from Q7 to Q4 days dosing:**
 - a. Day when regimen switched (since the first dose during Ext 1)**
- 3. Please provide subject IDs of the 10 subjects who discontinued the Q7D dosing and one subject who discontinued the Q4D dosing in Study 3859 Ext 1, and the reason for discontinuation.**
- 4. In Study 3859, please clarify the following regarding the actual treatment regimen that subjects received:**
 - a. How many subjects received Q3D dosing and how many received Q4D dosing in the main phase of the study?**
 - b. How many subjects received Q3D dosing and how many received Q4D dosing in the Ext 1 phase of the study?**
- 5. Please clarify why subject (b) (6) switched from Q7D to Q4D dosing in Ext 1 despite not having any bleeding events.**
- 6. In Study 3885, prophylactic dosing regimen was 50-75 IU/Kg twice weekly. Based on analysis of the submitted data, we note that 48 (71%) out of 64 subjects received a mean dose of >60 IU/kg. Please justify your proposed dosing of (b) (4) for children <12 years given that most subjects received higher dosing.**

Please confirm receipt of this communication, and do not hesitate to contact me, should you have any questions and/or concerns.

Warm regards,

Jean Dehdashti, MSc, RAC
Regulatory Project Manager

Center for Biologics and Evaluation
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-9146
Seameen.Dehdashti@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.